108 related articles for article (PubMed ID: 6751920)
1. Specific immunotherapy combined with whole body irradiation of BALB/c mice bearing Moloney murine sarcoma virus-induced primary tumors.
Kimura H; Yamaguchi Y; Fujisawa T
Gan; 1982 Jun; 73(3):446-53. PubMed ID: 6751920
[TBL] [Abstract][Full Text] [Related]
2. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
Cerundolo V; Lahaye T; Horvath C; Zanovello P; Collavo D; Engers HD
Eur J Immunol; 1987 Feb; 17(2):173-8. PubMed ID: 3030766
[TBL] [Abstract][Full Text] [Related]
3. Distribution of in vitro-stimulated immune lymphocytes in mice bearing Moloney murine sarcoma virus-induced primary tumor.
Kimura H; Yamaguchi Y
Gan; 1981 Feb; 72(1):72-80. PubMed ID: 7274651
[TBL] [Abstract][Full Text] [Related]
4. Suppression of Moloney sarcoma virus immunity following sensitization with attenuated virus.
Wood GW
Cancer Res; 1976 Dec; 36(12):4552-7. PubMed ID: 1000500
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody against IFN-gamma inhibits Moloney murine sarcoma virus-specific cytotoxic T lymphocyte differentiation.
Zanovello P; Vallerani E; Biasi G; Landolfo S; Collavo D
J Immunol; 1988 Feb; 140(4):1341-4. PubMed ID: 2830339
[TBL] [Abstract][Full Text] [Related]
6. Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.
Reichert CM; Rosenstein M; Von Glatz J; Hsu SM; Rosenberg SA
Lab Invest; 1985 Mar; 52(3):304-13. PubMed ID: 3974201
[TBL] [Abstract][Full Text] [Related]
7. Immunochemotherapy of transplantable Moloney leukemia with cyclophosphamide and allogeneic spleen lymphocytes and reversal of graft-versus-host disease with alloantiserum.
Kende M; Keys LD; Gaston M; Goldin A
Cancer Res; 1975 Feb; 35(2):346-51. PubMed ID: 234033
[TBL] [Abstract][Full Text] [Related]
8. Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro.
Cheever MA; Greenberg PD; Fefer A
Cancer Res; 1981 Jul; 41(7):2658-63. PubMed ID: 7018668
[TBL] [Abstract][Full Text] [Related]
9. T lymphocyte tolerance and early appearance of virus-induced cell surface antigens in Moloney-murine leukemia virus neonatally injected mice.
Collavo D; Zanovello P; Biasi G; Chieco-Bianchi L
J Immunol; 1981 Jan; 126(1):187-93. PubMed ID: 6969741
[TBL] [Abstract][Full Text] [Related]
10. Murine sarcoma virus pseudotypes used as immunogens against viral and chemical oncogenesis.
BasombrÃo MA; Mayer AM; Pasqualini CD
Cancer Res; 1977 Jun; 37(6):1768-76. PubMed ID: 192461
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T-cell-mediated antitumor effect of levamisole against murine syngeneic fibrosarcoma.
Gomi K; Morimoto M; Nomoto K
Cancer Res; 1982 Oct; 42(10):4197-202. PubMed ID: 6980702
[TBL] [Abstract][Full Text] [Related]
12. Antibody-dependent lymphocyte cytotoxicity in the murine sarcoma virus system: activity of IgM and IgG with specificity for MLV determined antigen(s).
Lamon EW; Skurzak HM; Andersson B; Whitten HD; Klein E
J Immunol; 1975 Apr; 114(4):1171-6. PubMed ID: 1117138
[TBL] [Abstract][Full Text] [Related]
13. Cell-mediated immunity to leukemia virus- and tumor-associated antigens in mice.
Herberman RB; Holden HT; Ting CC; Lavrin DL; Kirchner H
Cancer Res; 1976 Feb; 36(2 pt 2):615-21. PubMed ID: 56223
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice.
Kirchner H; Muchmore AV; Chused TM; Holden HT; Herberman RB
J Immunol; 1975 Jan; 114(1 Pt 1):206-10. PubMed ID: 122986
[TBL] [Abstract][Full Text] [Related]
15. Comparative immunological studies on cryosurgery and surgical operation using Moloney murine sarcoma virus-induced primary tumors in BALB/c mice.
Kimura H
Gan; 1978 Aug; 69(4):507-15. PubMed ID: 710802
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
Cohen P; Vourka-Karussis U; Weiss L; Slavin S
J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy of newly induced murine sarcomas.
Shu SY; Rosenberg SA
Cancer Res; 1985 Apr; 45(4):1657-62. PubMed ID: 3872168
[TBL] [Abstract][Full Text] [Related]
18. Tumor sponge implantation: an in vivo method for studying syngeneic, primary antitumor lymphocyte responses.
Vallera DA; Mentzer SJ; Maizel SE
Cancer Res; 1982 Feb; 42(2):397-404. PubMed ID: 7055792
[TBL] [Abstract][Full Text] [Related]
19. T cell-mediated immunity to oncornavirus-induced tumors. IV. Preliminary evidence for a specific suppression of anti-Moloney cell-mediated immune response by autoimmune T cells.
Leclerc JC; Plater C; Connan F; Debré P
Eur J Immunol; 1981 Jan; 11(1):45-7. PubMed ID: 6452279
[TBL] [Abstract][Full Text] [Related]
20. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
Donohue JH; Rosenstein M; Chang AE; Lotze MT; Robb RJ; Rosenberg SA
J Immunol; 1984 Apr; 132(4):2123-8. PubMed ID: 6607956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
